Stockscreener 앱 받기
5.0582
7.16%
-0.3918
전일 마감가:
$5.45
열려 있는:
$5.47
하루 거래량:
1.20M
Relative Volume:
0.74
시가총액:
$326.72M
수익:
$317.00K
순이익/손실:
$-53.47M
주가수익비율:
-2.6763
EPS:
-1.89
순현금흐름:
$-49.31M
1주 성능:
-5.07%
1개월 성능:
+2.64%
6개월 성능:
-40.40%
1년 성능:
+228.57%
1일 변동 폭
$4.92
$5.52
1주일 범위
$4.92
$5.82
52주 변동 폭
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
명칭
Immuneering Corp
전화
617-500-8080
주소
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
5.06 | 351.91M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.91 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.44 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.93 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.40 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 개시 | Leerink Partners | Outperform |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2024-03-15 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 개시 | Needham | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-04-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 개시 | Mizuho | Neutral |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 개시 | Chardan Capital Markets | Buy |
| 2022-04-01 | 개시 | Oppenheimer | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
모두보기
Immuneering Corp 주식(IMRX)의 최신 뉴스
Immuneering (IMRX) to Release Earnings on Thursday - MarketBeat
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - Yahoo Finance
Piper Sandler cuts Immuneering stock price target on launch timing - Investing.com
Why Immuneering Corporation stock could outperform in 2026Earnings Growth Report & Community Supported Trade Ideas - Naître et grandir
Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen - MarketBeat
Immuneering Corporation Q4 & Full Year 2025 Earnings: EPS Beats -$0.18 Estimate - Bayelsa Watch
Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com
Immuneering 2025 10-K: $0 Revenue, $(1.27) EPS and $(56.0)M Net Loss - TradingView
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - The Manila Times
Immuneering to Present at the Leerink Global Healthcare Conference - The Manila Times
IMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 - Yahoo Finance
IMRX Should I Buy - Intellectia AI
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Merger Talk: Does Immuneering Corporation outperform in volatile marketsJuly 2025 Market Mood & Reliable Volume Spike Alerts - baoquankhu1.vn
Investment Report: Does Immuneering Corporation meet Warren Buffetts criteriaPortfolio Update Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
Immuneering Corporation to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative
Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX - MarketBeat
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
What is Immuneering Corporation’s valuation compared to sector2025 Performance Recap & Long-Term Safe Investment Plans - mfd.ru
Empery Asset Management, LP Reduces Stake in Immuneering Corp - GuruFocus
Thomas Schall Buys 21,645 Shares of Immuneering (NASDAQ:IMRX) Stock - Defense World
Immuneering (NASDAQ:IMRX) Insider Harold Eugene Brakewood Purchases 5,250 Shares of Stock - MarketBeat
Immuneering’s (IMRX) chief business officer buys $24,990 in stock By Investing.com - Investing.com Australia
Immuneering’s (IMRX) chief business officer buys $24,990 in stock - Investing.com
Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 21,645 Shares of Stock - MarketBeat
Immuneering director Schall buys $101k in shares By Investing.com - Investing.com India
Immuneering director Schall buys $101k in shares - Investing.com
Immuneering Corporation (NASDAQ:IMRX) Short Interest Update - Defense World
Immuneering Corporation (NASDAQ:IMRX) Sees Significant Growth in Short Interest - MarketBeat
Insider Buying: Brett Hall Acquires Additional Shares of Immunee - GuruFocus
Hedge Fund and Insider Trading News: Ken Griffin, Bill Ackman, Michael Burry, Warren Buffett, Aurelius Capital Management, Balyasny Asset Management, Jain Global, Saba Capital Management, Bain Capital, Immuneering Corp (IMRX), Cloudflare Inc (NET) - Insider Monkey
Director of Immuneering Picks Up 1.8% More Stock - Yahoo Finance
Insider Buying: Leah Neufeld Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus
Immuneering chief people officer Neufeld buys $10,905 in IMRX By Investing.com - Investing.com Nigeria
Immuneering chief people officer Neufeld buys $10,905 in IMRX - Investing.com
Looking Into Immuneering Corp's Recent Short Interest - Sahm
Immuneering director Feinberg buys $86k in shares By Investing.com - Investing.com Nigeria
Immuneering director Feinberg buys $86k in shares - Investing.com
Iridian Asset Management LLC CT Makes New $1.93 Million Investment in Immuneering Corporation $IMRX - MarketBeat
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition - Yahoo Finance
Immuneering Corp (IMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
자본화:
|
볼륨(24시간):